SCHEMBL10063184

SCHEMBL10063184

O=C(Nc1ccc(N2CCOCC2)cc1)c1cc(-c2ccncc2)c[nH]c1=O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITK Q08881 3/20 0.83
▸ ALK Q9UM73 2/20 0.61
▸ MAPT P10636 3/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.57
▸ FLT3 P36888 2/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ INSR P06213 1/20 0.57
▸ NPM1 P06748 1/20 0.57
▸ IGF1R P08069 1/20 0.57
▸ BCR P11274 1/20 0.57
▸ AURKA O14965 2/20 0.56
▸ TTK P33981 2/20 0.56
▸ AURKB Q96GD4 2/20 0.56
▸ INCENP Q9NQS7 2/20 0.56
▸ KIT P10721 1/20 0.56
▸ SRC P12931 1/20 0.56
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ROCK1 Q13464 2/20 0.52
▸ NTRK1 P04629 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063186 0.91 ITK (1.00) ITKALKMAPTNPSR1FLT3
SCHEMBL10063196 0.90 ITK (0.83) ITKALKMAPTNPSR1FLT3
SCHEMBL10063188 0.89 ITK (0.81) ITKALKFLT3ABL1INSR
SCHEMBL10063194 0.89 ITK (0.81) ITKALKMAPTNPSR1FLT3
SCHEMBL10063189 0.86 ITK (0.77) ITKALKMAPTFLT3ABL1
SCHEMBL15850091 0.84 ITK (0.73) ITKALKMAPTNPSR1FLT3
SCHEMBL10081134 0.82 ITK (0.70) ITKALKMAPTNPSR1FLT3
SCHEMBL10063195 0.82 ITK (0.70) ITKALKMAPTFLT3ABL1
SCHEMBL10062893 0.81 ITK (0.84) ITKMAPTFLT3AURKATTK
SCHEMBL10063116 0.80 ITK (0.67) ITKALKMAPTFLT3INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831168-B1 PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. VERTEX PHARMA (US) 2014-07-02 — — EP disclosed
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ITK 393/4885ALK 581/4885MAPT 1299/4885
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ITK 393/4885ALK 581/4885MAPT 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback